Anlotinib suppresses metastasis and multidrug resistance via dual blockade of MET/ABCB1 in colorectal carcinoma cells

Anlotinib, a highly selective multi-targeted tyrosine kinase inhibitor (TKI) has therapeutic effects on non-small-cell lung cancer (NSCLC). In this study, the anti-tumor activity and molecular mechanism of anlotinib in metastatic colorectal cancer (mCRC) was explored. The anti-angiogenesis, anti-met...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Lin-Hai, Zhang, Di, Mo, Si-Si, Yuan, Hao, Mo, Xian-Wei, Zhao, Jin-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7974540/
https://www.ncbi.nlm.nih.gov/pubmed/33754008
http://dx.doi.org/10.7150/jca.45618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7974540/
https://www.ncbi.nlm.nih.gov/pubmed/33754008
http://dx.doi.org/10.7150/jca.45618

Ejemplares similares